groups (2-4) with decreased glomerular and tubular damage scores (Figure 1G). Most importantly, frequencies of CD8\(^{+}\)CD25\(^{+}\)FoxP3\(^{+}\) regulatory T cells were markedly reduced (Figure 1H).

**Conclusion:** MIC therapy inhibits progression of active lupus nephritis. Interestingly, preemptive MIC therapy was even able to prevent onset of disease with no significant disease activity at completion of the study. In accordance with our previous pre-clinical EAE regulatory B cells were significantly higher in MIC-treated groups (2-4) compared to control animals of group 1, whereas double negative T cells were markedly reduced (Figure 1H).

**Disclosure of Interests:** Clausius Speer Grant/research support from: From Research Grant from TolerogenixX GmbH, Daniela Kim Grant/research support from: Research Grant from TolerogenixX GmbH, Christian Kleist Shareholder of: TolerogenixX GmbH, Anita Schmitt Shareholder of: TolerogenixX GmbH, Matthias Schaier Shareholder of: TolerogenixX GmbH

**REFERENCES:**


**Disclosure of Interests:** Claudius Speer Grant/research support from: Research Grant from TolerogenixX GmbH, Daniela Kim Grant/research support from: Research Grant from TolerogenixX GmbH, Christian Kleist Shareholder of: TolerogenixX GmbH, Anita Schmitt Shareholder of: TolerogenixX GmbH, Michael Schmitt: None declared, Claudia Sommerer: None declared, Andrea Steinborn: None declared, Florian Käble: None declared, Christian Nussnag: None declared, Lei Wang Grant/research support from: Research Grant from TolerogenixX GmbH, Alexander Kunz Grant/research support from: Research Grant from TolerogenixX GmbH, Employee of: TolerogenixX GmbH, Hanns-Martin Lorenz: None declared, Martin Zeier: None declared, Christian Morath Shareholder of: TolerogenixX GmbH, Matthias Schaier Shareholder of: TolerogenixX GmbH

**DOI:** 10.1136/annrheumdis-2019-eular.873

**MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY**

Ronald van Vollenhoven\(^1\), George Tsokos\(^2\), Robert Gordon\(^3\), Kim Hung Lo\(^4\), Y Irene Gregan\(^5\), Kaiyin Fei\(^6\), Shawn Rose\(^7\), Bevra H. Hahn\(^8\), \(^1\) Amsterdam Rheumatol and Immunol Center ARCAD, Amsterdam, Netherlands; \(^2\) Beth Israel Hospital, Boston, United States of America; \(^3\) Janssen Research and Development, LLC, Spring House, United States of America; \(^4\) University of California LA, Los Angeles, United States of America

**Background:** Both IL-12 and IL-23 have been implicated in the pathogenesis of SLE. We have previously reported that treatment with an anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST) resulted in greater improvement in several SLE disease measures through week 24 compared with placebo (PBO). We have previously reported that treatment with an anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST) resulted in greater improvement in several SLE disease measures through week 24 compared with placebo (PBO).1

**Objectives:** Results of global and organ-specific disease measures and flares through year 1 are reported here.

**Methods:** We conducted a PBO-controlled phase 2 study in 102 patients with seropositive active SLE (defined by SLICC criteria, SLEDAI score >6, and ≥1 BILAG A and/or ≥2 BILAG B scores). Patients were randomized (3:2) to UST (6 mg/kg single IV infusion, then 90 mg SC q8w beginning at week 8, n=60) or PBO (n=42), both added to standard background therapy. Patients receiving PBO crossed over to UST (90 mg SC q8w) at week 24. The primary endpoint was the proportion of patients achieving SLE Responder Index (SRI)-4 response at week 24. Modified intention-to-treat (mITT) analyses across SLE disease measures were performed to evaluate maintenance of response with UST between week 24 and week 48 and severe BILAG flares (>1 new BILAG A score). Safety was assessed through week 56.

**Results:** As previously reported, SRI-4 response rate at week 24 was significantly greater (p = 0.0057) in patients receiving UST (62%) vs PBO (33%). In the UST group, SRI-4 (week 24: 62% vs week 48: 62%), SRI-5 (week 24: 43% vs week 48: 48%), and SRI-6 (week 24: 43% vs week 48: 47%) response rates were also sustained through 1 year in organ-specific disease measures (>50% improvement in active joint counts: week 24: 87% vs week 48: 87%; >50% improvement in GLS score: week 24: 53% vs week 48: 69%). In PBO patients who crossed over to UST at week 24 (n=33), response rates across outcomes studied were 10-20% higher at week 48 vs week 24. Flare rates for patients with severe BILAG flares were 2.1/10,000 patient-days in week 0-24 and 1.1/10,000 patient-days in week 24-48 in the UST group. In the PBO group, severe BILAG flare rates were 8.4/10,000 patient-days in week 0-24 and, following UST crossover, were 4.6/10,000 patient-days in week 24-48. The occurrence of severe BILAG flares seemed to diminish after approximately 8 weeks (week 8 in UST arm, week 32 in PBO arm) of treatment with UST (Figure). No deaths, malignancies, opportunistic infections, tuberculosis cases, or unexpected serious AEs (SAEs) were observed. Incidences of ≥1 SAE were UST (week 0-24) 8.3%, PBO (week 0-24) 9.5%, UST (week 24-48) 8.9%, and PBO-UST (week 24-48) 12.1%. Safety events were consistent with the known UST safety profile.

**Conclusion:** UST provided sustained clinical benefit in global and organ-specific SLE-activity measures and reduced flares through 1 year, with a safety profile consistent with other indications. Thus, UST may have durable therapeutic benefit in SLE.

**REFERENCE:**


**Disclosure of Interests:** Ronald van Vollenhoven Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche, and UCB, Consultant for: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex., Sponsors: AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex., George Tsokos Grant/research support from: Janssen Research & Development, LLC, Robert Gordon Employee of: Janssen Research & Development, LLC, Kim Hung Lo Employee of: Janssen Research & Development, LLC, Shawn Rose Employee of: Janssen Research & Development, LLC, Bevra H. Hahn Grant/research support from: Janssen Research & Development, LLC

**DOI:** 10.1136/annrheumdis-2019-eular.4449

**LONG-TERM EFFECTS OF SYNERGETIC B CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB COMBINATION TREATMENT IN SEVERE, REFRACTORY SLE: TWO YEAR RESULTS**

Tineke Kraai, E.J. Arends, Laura van Dam, Sylvia Kamerling, Paul L.A. van Daalen, Obbo Winne Bredewold, Angho Ray, Jaap Bakker, Ingeborg Bajema, Hans Ulrich Scherer, Thomas Huizinga, Ton Rabink, Cees van Kooten, Y.K. Onno Teng, Leiden University Medical Center (LUMC), Nephrology, Leiden, Netherlands; Erasmus MC, Division of Clinical Immunology, Rotterdam, Netherlands; Leiden University Medical Center (LUMC), Clinical Chemistry and Laboratory Medicine, Leiden, Netherlands; Leiden University Medical Center (LUMC), Pathology, Leiden, Netherlands; Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands

**Background:** We conducted a phase 2, proof-of-concept study (SynBioSe study) in which we combined rituximab and belimumab (RTX+BLM) for treatment of SLE patients with severe, refractory disease. We have previously reported that RTX+BLM effectively reduced relevant anti-nuclear autoantibodies (ANA) and showed a clinical response at 24 weeks.1

**Objectives:** The aim of the present study is to investigate the long-term immunological and clinical effects of RTX+BLM in severe, refractory SLE patients.
Methods: Fifteen severe, refractory SLE patients were included and followed for 2 years. Patients received RTX at week 0 and 2 and BLM at week 4, 6, 8 and then 4-weeks until week 104. Clinical response was assessed by achievement of low level of disease activity (LLDAS). By using specific antibody assays and high sensitivity flow cytometry (HS-FACS), we longitudinally followed, respectively, levels of SLE-specific ANAs and B-cell subsets.

Results: Ten patients (67%) showed a good clinical response after 24 weeks, referred to as ‘responders’. Two of these patients (13%) switched treatment after 24 weeks due to a pregnancy wish and 8 patients (53%) continued study throughout the complete 2 years of follow-up. Five patients (33%) discontinuation due to persistent LN (n=2), major flare (n=2) or relapsing minor flare (n=1), together referred to as ‘non-responders’. Responders achieved LLDAS at a median of 24 weeks [range 12-36] and remained in LLDAS for 76 weeks [56-92] out of 104 weeks of follow-up. In 7 patients with active LN, 6 obtained a complete renal response. In responders, ANAs showed significant and specific reduction throughout 2 years with achievement of seronegative anti-dsDNA immunofluorescence in 6 out of 6 of anti-dsDNA positive patients at baseline while total IgG, anti- tetanus and anti-rubella antibodies remained stable. By using HS-FACS, a median decrease of 97% [99;35] CD19+ B-cell depletion was achieved at 24 weeks. Long-term follow-up showed that B-cell repopulation was inhibited throughout 2 years with a persistent median decrease of 84% [92;22] compared to baseline. Further analysis of B-cell subsets revealed that in the responder, double negative (DN) B cells (CD27-IgD-) reached maximum depletion at 4 weeks (median 1.09*10^6 cells/liter [range 0.23*10^6-4.31*10^6]), which lasted up to week 72 with a median of 1.26*10^6 cells/liter [0.79*10^6-4.11*10^6] at week 72, similar to values at nadir. This was in contrast to non-responders, where maximum depletion of DN B-cells was reached at 12 weeks (0.48*10^6 [0.17*10^6-5.86*10^6]), after which these cells increased to 2.29*10^6 [0.49*10^6-4.39*10^6] at 24 weeks.

Conclusion: Over 2 years follow-up, RTX+BLM for severe, refractory SLE patients prevented complete B-cell repopulation with persistent and specific reduction of ANAs. Clinical response was observed in 67% of patients and treatment discontinuation due to high disease activity was associated with early repopulation of DN B-cells. These data warrant further studies on clinical and immunological benefits of combination treatment RTX+BLM.

REFERENCE:


OP0043 WITHDRAWAL OF A LOW DOSE (5 MG) OF CORTICOSTEROIDS IN SYSTEMIC LUPUS IN REMISSION FOR MORE THAN A YEAR IS AT RISK OF RELAPSE – THE CORTICOLIP Trial

Micheline Pha,1 Alexis Mathian,2,3, Julien Haroche,2,4 Miguel Hié1, Fleur Cohen1, Du Boulin-Le Th Huong2, Marc Pineton de Chambrun4, Patrick Cherkin1,4 Hôpital Saint-Raphaël, Marseille, France;1 Groupement Hospitalier R-Sapétiére, Assistance Publique–Hôpitaux de Paris (APHP), Rare Diseases Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Rare Autoimmune Diseases, Service de Médecine Interne 2, Paris, France;2 Sorbonne Université, Centre d’Immunologie et des Maladies Infectieuses (CIM), Inserm U1135, Paris, France;3 Centre Hospitalier Universitaire de Dijon, Hôpital François Mitteier, Service de Médecine interne et Maladies infectieuses, Dijon, France;4 Centre Hospitalier Universitaire de Dijon, Hôpital François Mitteier, Centre d’Investigation Clinique, Inserm CIC 1432, Dijon, France

Background: Glucocorticoids (GCs) are a mainstay of treatment for patients with SLE but are associated with significant adverse effects. Some SLE patients are maintained for a long-term under a low dose of prednisone to prevent relapse. There is no scientific data to sustain this therapeutic strategy.

Objectives: We hypothesized that maintaining a daily dose of 5 mg prednisone in patients with an inactive SLE for at least a year would prevent the risk of relapse.

Methods: The CORTICOLIP study (NCT02356517) was a prospective random- ized, open-labeled, controlled, monocentric study sought to compare maintenance vs withdrawing of low-dose of prednisone (5mg) to reduce SLE flares, conducted from January 2014 to March 2017. Inclusion criteria were SLE patients who during the year preceding the inclusion had 1/an inactive SLE defined by a SLEDAI-2K score ≤4, a BILAG-2004 index C, D or E in all systems and a PGA =0 and 2/a stable SLE treatment including prednisone 5 mg daily. The primary end point was the number of patients with flares during 12 months of follow-up defined by the revised-SELENA SLEDAI Flare Index (rSFI). Secondary outcomes were occurrence of a BILAG scores A or B >1, clinical SLEDAI-2K >0, PGA >0.5 and increase of the SLICC damage index (SDI). All patients were included in the intention-to-treat analysis.

Results: A total of 124 patients (61 in the maintenance group and 63 in the withdrawal group) were included. No patients were lost to follow up. At baseline There were no significant differences between the maintenance and the withdrawal group with respect to: duration of SLE [mean (standard deviation) duration of 11.8 (±6.9) years, duration of remission [56.7 (±58.6) months], HCO treatment [96.2% vs 100.0%], immunosuppressive drugs [27.9% vs 25.4%], previous renal involvement [34.4% vs 41.3%], low C3 [16.4% vs 15.9%], positive Farr test [47.5% vs 46.0%], and SDI [mean index of 0.5 (±0.1) vs 0.7 (±0.2)].

There were significantly more flares in the withdrawal group compared to the maintenance group (17 flares versus 4, p=0.0034 using the Fisher’s exact test), Mild or moderate flares were more frequent in the withdrawal group compared to the maintenance group (12 vs 3, p=0.029). The occurrence of severe flare was not significantly different between the two groups (5 vs 1, p = 0.208). More than two-thirds of the flares in the withdrawal group occurred within the first six months. Within the withdrawal group, using forest plot analysis, no significant association was found between the occurrence of a flare and age, sex, duration of SLE, duration of SLE remission, duration of GCs treatment, immunosuppressants and soro- logical SLE activity at randomization. Four patients in the withdrawal group and none in the maintenance group experienced damage: 2 osteoporosis bone frac- tures, 1 hydroxycholecholic retinopathy and 1 cataract.

Conclusion: Withdrawal of low dose of steroids in patients with inactive SLE and stable therapeutic regimen for more than a year is associated with a high risk of relapse.

Disclosure of Interests: None declared.


OP0044 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE GONADOTOXIC EFFECTS OF CYCLOSPHOSHAMIDE AND BENEFITS OF GONADOTROPIN RELEASING HORMONE ANALOGUES IN WOMEN OF CHILD-BEARING AGE WITH AUTOIMMUNE RHEUMATIC DISEASE

Shi-Nan Luong1,2, Anthony Isaacs3, Fang En Sin1, Ian Gilles1.1 University College London, London, United Kingdom; 2University of New South Wales, Sydney, Australia; 3Northwick Park Hospital, London, United Kingdom

Background: Premature ovarian insufficiency (POI) is a side effect of intrave- nous cyclophosphamide (i.v.CYC), which is the treatment of choice for many severe manifestations of autoimmune rheumatic disease (ARD) (1). The risk of POI post-CYC appears to be dependent on cumulative dose and patient age but has not been precisely quantified. Gonadotropin Releasing Hormone Analogues (GnRhA) may reduce this risk (2). The occurrence of severe flare was not significantly different between the two groups (5 vs 1, p = 0.208). More than two-thirds of the flares in the withdrawal group occurred within the first six months. Within the withdrawal group, using forest plot analysis, no significant association was found between the occurrence of a flare and age, sex, duration of SLE, duration of SLE remission, duration of GCs treatment, immunosuppressants and sero- logical SLE activity at randomization. Four patients in the withdrawal group and none in the maintenance group experienced damage: 2 osteoporosis bone frac- tures, 1 hydroxycholecholic retinopathy and 1 cataract.

Conclusion: Withdrawal of low dose of steroids in patients with inactive SLE and stable therapeutic regimen for more than a year is associated with a high risk of relapse.

Disclosure of Interests: None declared.